Aldeyra Therapeutics Inc Investor Relations Material
Latest events
Study Result
Aldeyra Therapeutics Inc
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Aldeyra Therapeutics Inc
Access all reports
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma.
Key slides for Aldeyra Therapeutics Inc
Corporate Presentation
Aldeyra Therapeutics Inc
Corporate Presentation
Aldeyra Therapeutics Inc
Latest articles
Daniel Ek: Co-founder and CEO of Spotify
Explore Daniel Ek's journey from a tech-savvy teenager to the co-founder and CEO of Spotify and the most influential person in the music industry.
28 Mar 2024
Companies That Had Their IPO in 1992: A Cautiously Optimistic Market
1992 marked a relatively cool IPO landscape and stock market sentiment, in the wake of the early 90s recession.
28 Mar 2024
Remembering Daniel Kahneman: Transforming Psychology and Economics
Explore Daniel Kahneman's legacy in psychology and economics, highlighting his impact on decision-making and behavioral economics.
28 Mar 2024
Ticker symbol
Country
🇺🇸 United States